| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/30/2003 | US20030021802 Genetic engineering; diagnosing gastrointestinal disorders |
| 01/30/2003 | US20030021801 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia |
| 01/30/2003 | US20030021800 Diagnosing infections; calibration using antibodies |
| 01/30/2003 | US20030021798 Use of mCRP to enhance immune responses |
| 01/30/2003 | US20030021797 Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus |
| 01/30/2003 | US20030021796 Method of enhancing T cell immunity by selection of antigen specific T cells |
| 01/30/2003 | US20030021795 Administering antibody; determination binding to peptide |
| 01/30/2003 | US20030021794 Heat shock protein-based vaccines and immunotherapies |
| 01/30/2003 | US20030021793 Polyanionic polymers as adjuvants for mucosal immunization |
| 01/30/2003 | US20030021792 Quantitative analysis; immunosuppressants, anticoagulants |
| 01/30/2003 | US20030021789 Infection therapy |
| 01/30/2003 | US20030021788 Novel human STRA6-like protein and nucleic acids encoding the same |
| 01/30/2003 | US20030021786 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/30/2003 | US20030021785 Use of rank antagonists to treat cancer |
| 01/30/2003 | US20030021781 Administering antibodies |
| 01/30/2003 | US20030021779 Immunology response; monoclonal antibodies |
| 01/30/2003 | US20030021778 Ocular treatment by topical application of an immunoglobulin |
| 01/30/2003 | US20030021770 Vaccines |
| 01/30/2003 | US20030021769 Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer |
| 01/30/2003 | US20030021766 Nucleic acid mucosal immunization |
| 01/30/2003 | US20030021765 Polymer conjugates of interferon beta-1a and uses |
| 01/30/2003 | CA2730856A1 Capsular polysaccharide solubilisation and combination vaccines |
| 01/30/2003 | CA2454226A1 Improved heteropolymer complexes and methods for their use |
| 01/30/2003 | CA2454185A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453959A1 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres |
| 01/30/2003 | CA2453342A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 01/30/2003 | CA2453260A1 Vaccine formulation potentiated by the combination of a dna and an antigen |
| 01/30/2003 | CA2452518A1 Inhibition of behab cleavage and primary central nervous system (cns) tumors |
| 01/30/2003 | CA2452421A1 Anti-microbial targeting chimeric pharmaceutical |
| 01/30/2003 | CA2450692A1 Tumor antigen |
| 01/29/2003 | EP1279735A1 Malaria plasmodium antigen polypeptide se36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen |
| 01/29/2003 | EP1279679A1 Composition containing leishmania lip2a |
| 01/29/2003 | EP1279678A1 Gag antigen and other orf fragments of lav virus. Use for the detection of lav infection and in immunogenic compositions |
| 01/29/2003 | EP1279677A1 Gd3-mimetic peptides |
| 01/29/2003 | EP1279404A1 Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| 01/29/2003 | EP1279401A1 Oil in water emulsions containing saponins |
| 01/29/2003 | EP1278870A1 Splice variant of camp phosphodiesterase type 7 (pde7a3) |
| 01/29/2003 | EP1278856A2 Immunogenic pneumococcal protein and vaccine compositions thereof |
| 01/29/2003 | EP1278855A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/29/2003 | EP1278854A2 Compositions and methods for the therapy and diagnosis of acne vulgaris |
| 01/29/2003 | EP1278853A2 Listeria monocytogenes genome, polypeptides and uses |
| 01/29/2003 | EP1278851A1 Humanised antibodies to the epidermal growth factor receptor |
| 01/29/2003 | EP1278849A2 Thrombopoietin receptor modulating peptide |
| 01/29/2003 | EP1278844A2 G protein-coupled receptors |
| 01/29/2003 | EP1278843A2 Rna metabolism proteins |
| 01/29/2003 | EP1278842A2 Dna encoding the prost 03 polypeptide |
| 01/29/2003 | EP1278826A1 Novel proteins |
| 01/29/2003 | EP1278825A2 Methods of producing membrane vesicles |
| 01/29/2003 | EP1278824A2 Clearance of ras-mediated neoplastic cells from mixed cellular compositions using reovirus |
| 01/29/2003 | EP1278823A2 Clearance of neoplastic cells from mixed cellular compositions using viruses |
| 01/29/2003 | EP1278774A2 Human g-protein coupled receptors |
| 01/29/2003 | EP1278769A2 Tuberculosis antigens and methods of use thereof |
| 01/29/2003 | EP1278768A1 Method for identifying helicobacter antigens |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278766A2 Polynucleotides for diagnosing mammary gland cancer |
| 01/29/2003 | EP1278765A2 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use |
| 01/29/2003 | EP1278764A2 Compounds and methods for the treatment and prevention of bacterial infection |
| 01/29/2003 | EP1278551A2 Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
| 01/29/2003 | EP1278548A2 Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| 01/29/2003 | EP1278546A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents |
| 01/29/2003 | EP1278545A1 Combination therapy of respiratory diseases using antibodies |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278543A2 Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 01/29/2003 | EP1278542A2 Molecular antigen arrays and vaccines |
| 01/29/2003 | EP1278541A1 Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines |
| 01/29/2003 | EP1278540A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 01/29/2003 | EP1278539A1 Omp protein associated with autologous and/or heterologous tumour cell lysate |
| 01/29/2003 | EP1278538A1 Cd18-binding antibodies inhibit stenosis-related disorders |
| 01/29/2003 | EP1278535A2 Uses of tgap7 for the modulation of leucocyte activation |
| 01/29/2003 | EP1278534A1 Methods and compositions for impairing multiplication of hiv-1 |
| 01/29/2003 | EP1002110B1 Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins |
| 01/29/2003 | EP0841942B1 Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine |
| 01/29/2003 | EP0753005B1 Cytotoxic t-cell lymphocyte ("ctl") activity regulation by class i mhc peptides |
| 01/29/2003 | EP0703980B1 Intracellular binding proteins and use thereof |
| 01/29/2003 | CN1394138A Hair growth stimulant |
| 01/29/2003 | CN1099894C Vaccine composition for eliciting immune response against N-glycolylated gangliosides and its use |
| 01/28/2003 | US6512101 Branched hydrazone linkers |
| 01/28/2003 | US6512096 Prostate cell surface antigen-specific antibodies |
| 01/28/2003 | US6511845 Methods for producing an immune response against HIV-1 |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511801 HIV-1 group O strain gp160 env precursor protein comprising the amino acid sequence of SEQ ID NO:100 |
| 01/28/2003 | US6511677 Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| 01/28/2003 | US6511667 Attenuated dengue-2 virus vaccine |
| 01/28/2003 | US6511666 Purified antigenic complex comproised of multimeric protein complexes of arginine- and lysine-specific thiol endopepti-dases containing adhesion domains; raising antibody response against porphyromonas gingivalis |
| 01/28/2003 | US6511662 Treatment of cytomegalovirus using aminopeptidase N |
| 01/28/2003 | CA2072008C Immunologically active proteins from borrelia burgdorferi, related test kits which contain these proteins and are suitable for detecting antibodies in test fluids, and the use of these proteins as vaccines against infections caused by borrelia strains |
| 01/27/2003 | WO2002009745A1 Medicament for the immunotherapy of malignant tumours |
| 01/27/2003 | CA2417374A1 Medicament for the immunotherapy of malignant tumours |
| 01/24/2003 | WO2002008456A2 Method for identifying metastatic tumor cells |
| 01/24/2003 | CA2416697A1 Method for identifying metastasizing tumor cells |
| 01/23/2003 | WO2003006995A2 Method for identifying substances which modulate interleukin 4 (il-4) signaling |
| 01/23/2003 | WO2003006893A2 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | WO2003006672A2 Antimicrobial nucleic acid antibodies, and materials and methods for making and using same |
| 01/23/2003 | WO2003006665A1 Lawsonia intracellularis |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006640A1 A specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it |
| 01/23/2003 | WO2003006611A2 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE |